BioLife Solutions, Inc. (NASDAQ:BLFS – Get Free Report) EVP Aby J. Mathew sold 1,597 shares of BioLife Solutions stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $39,925.00. Following the sale, the executive vice president now directly owns 260,601 shares of the company’s stock, valued at $6,515,025. This represents a 0.61 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
BioLife Solutions Trading Down 4.6 %
Shares of BLFS stock traded down $1.21 during trading hours on Thursday, hitting $25.06. 278,326 shares of the company’s stock traded hands, compared to its average volume of 349,466. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55. The stock has a market cap of $1.18 billion, a PE ratio of -23.64 and a beta of 2.04. The stock’s 50 day simple moving average is $26.64 and its 200 day simple moving average is $25.51.
BioLife Solutions (NASDAQ:BLFS – Get Free Report) last announced its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the previous year, the business earned ($0.21) EPS. On average, sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.
Institutional Trading of BioLife Solutions
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the stock. TD Cowen lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. KeyCorp raised their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Craig Hallum upped their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright raised their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Finally, Northland Securities upped their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.86.
Check Out Our Latest Analysis on BLFS
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Articles
- Five stocks we like better than BioLife Solutions
- Most Volatile Stocks, What Investors Need to Know
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Where Do I Find 52-Week Highs and Lows?
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Using the MarketBeat Stock Split Calculator
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.